Form 4 for ABT Abbott Laboratories
Accepted 2022-02-23 00:00:00 ET · period of report 2022-02-18 · accession 0001415889-22-001741 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-23 | 2022-02-18 | ABT | Mateus Fernando | SVP | A - Grant | $0.00 | +10.5K | 19.1K | +121% | $0 |
| DM | 2022-02-23 | 2022-02-19+ | ABT | Mateus Fernando | SVP | F - Tax | $116.79 | -2,182 | 17.0K | -11% | -$254.8K |
| D | 2022-02-23 | 2022-02-18 | ABT | Mateus Fernando | SVP | A - Grant | $0.00 | +48.9K | 48.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2022-02-18 | A | A | 10,482 | $0.00 | 19,142 | D | — | — | (F1) These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. |
| 2 | Common | Common shares without par value | 2022-02-19 | F | D | 595 | $116.79 | 18,547 | D | — | — | |
| 3 | Common | Common shares without par value | 2022-02-21 | F | D | 701 | $116.79 | 17,846 | D | — | — | |
| 4 | Common | Common shares without par value | 2022-02-22 | F | D | 886 | $116.79 | 16,960 | D | — | — | |
| 5 | Derivative | Option (right to buy) | 2022-02-18 | A | A | 48,852 | $0.00 | 48,852 | D | $117.58 · 2023-02-18 to 2032-02-17 | 48,852 Common Shares | (F2) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,284 on February 18, 2023, 16,284 on February 18, 2024, and 16,284 on February 18, 2025. |